INTRODUCTION
Survival in metastatic castration-resistant prostate cancer (mCRPC) patients remains limited and treatment is complicated by tumor heterogeneity. As antibody-based therapeutics emerge, identifying actionable antigen targets and patient subgroups most likely to benefit is essential.
MATERIALS & METHODS
Ge...
Tanja C. van Dijk, M. Smid, D. Robbrecht et al.· European Journal of Cancer· 0 citations
This pooled analysis of 15,731 cases showed that nulliparity, age at menopause, MHT, and BMI have independent, dose-response associations with ER, PR, and grade, clarifying patterns of etiologic heterogeneity.
Daniel Adams, Amber N. Hurson, T. Ahearn et al.· Journal of the National Canc...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.